NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. Interim ...

Founded in 1998, SGC has earned its reputation as one of the most reliable grading companies in the hobby. Its iconic black ...

From reference managers to note-taking apps, and presentation tools, the research and writing process is getting a high-tech ...

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today ...

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to ...

To make the most of your techUK website experience, please login or register for your free account here. Catch up with this recording of our recent "Maximise Your Membership" presentation for techUK's ...

TOYOTA Motor Corp. formally unveiled the next chapter of its most revered nameplate — the Century — during the opening of the Japan Mobility Show.

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient populationEncouraging safety and ...

Connect Biopharma Holdings Limited ( CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases November 3, 2025 4:15 PM EST ...

The designs included elements like a new intercity bus station, a soaring, glass-walled addition to the Race Street front ...

In today’s rapidly evolving tech landscape, centralized architectural decision-making can become a bottleneck to delivery ...

Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/ ...